Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

VERAXA, Ardigen launch drug discovery collaboration

VERAXA Biotech (NASDAQ: VRXA) has announced a collaboration with closely held AI partner Ardigen to support VERAXA’s growing BiTAC pipeline of T-cell engagers and antibody-drug conjugates. According to VERAXA, the...

July 13, 2026

Developments

Virax signs immune profiling product supply deal with Fosun

Virax Biolabs (NASDAQ: VRAX) has announced the signing of an exclusive commercial supply agreement with Fosun Diagnostics, a subsidiary of Fosun Pharma (600196.SS; 02196.HK), for its research-use-only ImmuneSelect...

July 13, 2026

Developments

FDA grants RPD to Thiogenesis’ TTI-0102 for Leigh syndrome

Thiogenesis Therapeutics (TSXV: TTI; OTCQX: TTIPF) has announced that the FDA has granted Rare Pediatric Disease (RPD) designation to its lead candidate, TTI-0102, for the treatment of Leigh syndrome. Upon approval of a...

July 13, 2026

Developments

MIRA reports positive results supporting MIRA-55 as non-opioid oral pain therapy

MIRA Pharmaceuticals (NASDAQ: MIRA) has announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, the company’s oral drug candidate being developed as a non-opioid...

July 10, 2026

Developments

Analysis shows 22% cut in NICU admissions in first-time pregnancies with Sera’s PreTRM

Sera Prognostics (NASDAQ: SERA) has announced publication of a new subgroup analysis from the PRIME trial demonstrating that its PreTRM Test-guided care in first-time pregnancies significantly improved neonatal...

July 10, 2026

Developments

Rani and PegBio join forces to expand obesity pipeline

Rani Therapeutics Holdings (NASDAQ: RANI) has announced a research and development collaboration with PegBio (SEHK: 2565) to explore the delivery of multiple novel candidates from PegBio’s obesity and metabolic...

July 10, 2026

Developments

Evogene and BCDD collaborate in drug discovery initiative

Evogene (NASDAQ: EVGN; TASE: EVGN) and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating...

July 9, 2026

Developments

CervoMed completes enrollment for study of neflamapimod in nfvPPA

CervoMed (NASDAQ: CRVO) has announced that it has completed enrollment in the Phase 2a study to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in patients with nonfluent/agrammatic variant...

July 9, 2026

Developments

First patient dosed in Delcath’s global trial of HEPZATO in mBC

Delcath Systems (NASDAQ: DCTH) has announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy, in its global Phase 2 clinical trial evaluating HEPZATO in combination with...

July 9, 2026

Developments

MAIA reports strong data from trial of 3L therapy in NSCLC

MAIA Biotechnology (NYSE American: MAIA) has announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action...

July 9, 2026

Developments

FDA grants RPDD to Vanda’s investigational CMT2S therapy

Vanda Pharmaceuticals (NASDAQ: VNDA) has announced that the FDA has granted Rare Pediatric Disease Designation (RPDD) to its investigational antisense oligonucleotide therapy—VCA-894A—for the treatment of Charcot-Marie...

July 8, 2026

Markets

WB starts Zura Bio at OP; sum-of-the-parts NPV estimate $13.90

William Blair launched coverage of Zura Bio (NASDAQ:ZURA) with an “outperform” rating and sum-of-the-parts NPV estimate of $13.90. The stock closed at $5.08 on July 7. Zura is a clinical-stage, multi-asset immunology...

July 8, 2026

Subscribe